Back to Journals » OncoTargets and Therapy » Volume 3

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes

Authors Garcia, Jain N, Godley L

Published 25 February 2010 Volume 2010:3 Pages 1—13

DOI https://doi.org/10.2147/OTT.S7222

Review by Single-blind

Peer reviewer comments 2


Jacqueline S Garcia1, Nitin Jain1, Lucy A Godley1,2

1Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA; 2Cancer Research Center, The University of Chicago, Chicago, IL, USA

Abstract: Myelodysplastic syndromes (MDS) are clonal bone marrow malignancies characterized by peripheral cytopenias and dysplastic changes in the bone marrow with various clinical features. Patients with MDS, in particular those with intermediate-2 (Int-2) and high-risk disease, have a poor prognosis. The mainstay of treatment includes cytoxic chemotherapy and supportive care. Over the last decade, promising results from studies focusing on hypomethylating agents, such as decitabine (5-aza-deoxycytidine) and 5-azacitidine, have led to the expansion of the therapeutic arsenal for MDS. This review presents the current data available on the clinical efficacy and safety profile for decitabine as a treatment for MDS. Although not fully understood, decitabine’s antitumor activity may involve its ability to induce hypomethylation and reactivation of genes responsible for cellular differentiation, stimulate an immune response, induce DNA damage/apoptotic response pathways, and/or augment stem cell renewal. Future studies that use epigenetic therapies that combine hypomethylating agents with histone deacetylase inhibitors (HDACi) and head-to-head comparison studies of decitabine and 5-azacitidine will provide valuable pre-clinical and clinical data, enhancing our understanding of these drugs.
Keywords: decitabine, 5-aza-deoxycytidine, 5-azacitidine, myelodysplastic syndromes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]